Resource Summary Report

Generated by RRID on Sep 6, 2026

4T1-Luc2 [ATCC]

RRID:CVCL_A4BM
Type: Cell Line

Proper Citation

RRID:CVCL_A4BM

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A4BM

Proper Citation: RRID:CVCL_A4BM

Description: Cell line 4T1-Luc2 [ATCC] is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Comments: Characteristics: Stably expresses firefly luciferase under the control of the human EF1a promoter (ATCC=CRL-2539-LUC2).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: 4T1-Luc2 [ATCC]

Cross References: ATCC:CRL-2539-LUC2, Wikidata:Q105505946

ID: CVCL_A4BM

Hierarchy: cvcl_0125

Record Creation Time: 20220427T215055+0000

Record Last Update: 20260905T184329+0000

Ratings and Alerts

No rating or validation information has been found for 4T1-Luc2 [ATCC].

No alerts have been found for 4T1-Luc2 [ATCC].

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Hu M, et al. (2026) Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity. Cancer cell, 44(5), 965.

Nguyen TQA, et al. (2026) Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. Cell reports. Medicine, 7(5), 102750.

Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. Cell reports. Medicine, 7(6), 102844.

Qu C, et al. (2026) Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. Cell reports. Medicine, 7(7), 102843.

Sun M, et al. (2026) Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer. Cell reports. Medicine, 7(5), 102763.

Fan G, et al. (2026) Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways. Cancer cell, 44(6), 1160.

Ermogenous C, et al. (2026) MIF mediates monocyte-dependent inhibition of natural killer cell cytotoxicity in triple-negative breast cancer. Cell reports, 45(6), 117431.

Zhang J, et al. (2025) Enabling tumor-specific drug delivery by targeting the Warburg effect of cancer. Cell reports. Medicine, 6(1), 101920.

Gu Y, et al. (2025) Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. Angiogenesis, 28(2), 13.

Koltun B, et al. (2025) Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug Resistance. Molecular cancer therapeutics, 24(11), 1815.

Laplante P, et al. (2025) Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model. Neoplasia (New York, N.Y.), 62, 101145.

Zhang Y, et al. (2024) Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer. Cell metabolism, 36(1), 193.

Wang Z, et al. (2023) Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. Nature biomedical engineering, 7(9), 1188.

Beziaud L, et al. (2023) IFN??-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. Cell stem cell, 30(6), 818.

Amano T, et al. (2023) Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity. iScience, 26(4), 106335.

Shen JZ, et al. (2022) A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. Molecular cell, 82(6), 1123.